MENLO PARK, Calif., April 8, 2024 /PRNewswire/ — Edison Oncology Holding Corp. (“Edison Oncology”), a privately held biopharmaceutical company, today announced the presentation of positive interim data from the company’s ongoing multicenter Phase 1/2a clinical trial of Orotecan (oral…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.